CompletedPhase 2NCT00803933
Trial of DB289 for the Treatment of Stage I African Trypanosomiasis
Studying African trypanosomiasis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Immtech Pharmaceuticals, Inc
- Principal Investigator
- Victor Kande, MDProgramme Nationale de Lutte contre la Trypanosomiase Humaine Africaine
- Intervention
- DB289(drug)
- Enrollment
- 111 enrolled
- Eligibility
- 15-50 years · All sexes
- Timeline
- 2003 – 2005
Study locations (2)
- CDTC Maluku, Gombé, Kinshasa, Republic of the Congo
- Vanga Hospital, Gombé, Kinshasa, Republic of the Congo
Collaborators
Bill and Melinda Gates Foundation
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00803933 on ClinicalTrials.govOther trials for African trypanosomiasis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07106385The Effectiveness of Repetitive Transcranial Magnetic Stimulation (rTMS) on Improving Sleep Quality in Adults Without Serious Mental IllnessThe University of Hong Kong
- ACTIVE NOT RECRUITINGNCT04565769Cognitive Function in Melanoma Patients Treated With Adjuvant Immune Checkpoint InhibitorsAarhus University Hospital
- RECRUITINGNCT01778504Studying Childhood-onset Behavioral, Psychiatric, and Developmental DisordersNational Institute of Mental Health (NIMH)